RxDoctor Payments Data

Daniel Wesemann

Psychiatric/Mental Health · Davenport, IANPI 1366435125

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (42.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 95.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $8,450 and has fallen 96.3% since, to $316 in 2025. Among psychiatric/mental health clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,957in general payments, 2019–2025

Across 46 payments — averaging $325.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$14K
  • E.r. Squibb & Sons, L.L.C.$149
  • Axsome Therapeutics, Inc.$125
  • Johnson & Johnson$96
  • Teva Pharmaceuticals USA, Inc.$86
  • AbbVie$71
  • plus $197 from 4 others

What the payments were for

  • Consulting fees$6,37543%
  • Speaking & faculty fees$3,00020%
  • Travel & lodging$3,67325%
  • Food & beverage$1,88213%
  • Education$270%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,957 in reported general payments places this provider in the 95th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$9,612
Medicare patients
31
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide23$11,018
BelsomraSuvorexant14$6,261
Aripiprazole85$3,838
Desvenlafaxine Succinate ErDesvenlafaxine Succinate48$1,974
Bupropion XlBupropion Hcl64$1,860
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine13$1,835
Fluvoxamine Maleate12$1,525
Duloxetine Hcl52$1,083
Quetiapine Fumarate61$1,078
Oxcarbazepine11$783
Buspirone Hcl44$677
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$642
Venlafaxine Hcl ErVenlafaxine Hcl30$627
Escitalopram Oxalate61$548
Trazodone Hcl51$543

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →